The Stanford Department of Neurosurgery is now accepting applications for the 2026-2027 Clinical Fellowship in Neurosurgical Oncology and Stereotactic Radiosurgery. Under the direction of Dr. Steven D. Chang, this one-year GME program offers specialized training in CyberKnife treatment planning and delivery for a diverse range of oncologic and functional conditions.

Interested applicants who have completed an ACGME-accredited residency within the U.S or have 24 of months of Board-approved postgraduate training should email their CV, personal statement, and three letters of recommendation to Dr. David J. Park at djpark@stanford.edu

About 40% of all men will develop prostate cancer during their lifetime, with over 65,000 new cases diagnosed annually in Germany [1]. Age is a key risk factor, as most cases occur in men aged 65 or older.

“With robot-guided stereotactic radiosurgery (SBRT), we are now able to treat localized prostate cancer – especially intermediate-risk cases – very effectively in many patients,” says Alexander Muacevic, MD, Director of the European Radiosurgery Center Munich (ERCM).

The completed HYPOSTAT-II trial, involving 464 participants – 249 of whom were treated at the ERCM – confirms that SBRT is well tolerated and associated with high patient satisfaction. Results to date are comparable to those of the PACE trials, whose findings contributed to the inclusion of radiosurgery in the German S3 clinical guidelines (the highest level of evidence-based medical guidelines in Germany) in 2025.

Integrating 3D printing technology has emerged as a game-changer in the healthcare system, enhancing workflow and treatment quality.

The Division of Medical Physics at Stanford has led the charge in this area with a dedicated faculty team developing innovative solutions that address longstanding challenges in radiation therapy.

The 2025 Global Radiotherapy Impact Report brings together leading experts from across radiation oncology, including voices well-known to the RSS community, to highlight how advanced radiotherapy, including SBRT and SRS, is transforming cancer care worldwide. Convened by Elekta, the report illustrates compelling clinical outcomes, patient quality of life, and the growing evidence behind high-precision, adaptive, and ablative treatments. It also underscores an urgent truth: expanding access to radiotherapy could save up to 1 million lives each year. RSS members can use this report to stay informed, advocate, and advance the future of precision radiation medicine.